Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGX101
- Development stage
- Preclinical
- Lead developer
- Soligenix
01
Overview
SGX101 is an investigational therapeutic developed for the treatment of melioidosis. Melioidosis is an infectious disease caused by the bacterium Burkholderia pseudomallei. Although specific mechanistic and modality details for SGX101 are not publicly disclosed, it is mentioned within research programs and company pipelines focused on biodefense and infectious disease applications. SGX101 is possibly under the development of Soligenix in collaboration or research with Precigen, but detailed publicly available preclinical or clinical data about its composition, mechanism of action, or status are limited.
- Brand names
- SGX101SGX-101SGX 101
- Other names
- SGX 101SGX101SGX-101
Beyond the preview
Go deeper on SGX101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGX101.